Navigation Links
Codiak BioSciences Closes $61 Million Series B Financing
Date:1/26/2016

CAMBRIDGE, Mass., Jan. 26, 2016 /PRNewswire/ -- Codiak BioSciences Inc., a leading company in the field of exosome biology, today announced the closing of its $61 million Series B round, bringing total investment in its combined Series A and B financing, announced in November 2015, to $92 million. Codiak intends to use the proceeds of this round primarily to advance research and clinical development of exosomes for therapeutic and diagnostic purposes. 

The Series A and B financing were co-led by ARCH Venture Partners and Flagship Ventures, with participation by the Alaska Permanent Fund, Alexandria Venture Investments and Fidelity Management and Research Company.

"This financing is a strong indication of the promise of exosomes to improve human health," said Douglas E. Williams, Ph.D., President and CEO. "With these additional resources we will continue to build our world-class team to realize the broad transformative potential of exosomes for multiple therapeutic and diagnostic uses."

About Exosomes

Exosomes are tiny membrane sacs, or vesicles, that are released by both healthy and cancerous cells. Substances from cell cytoplasm, including genomic DNA, various RNA species, proteins and lipids are encapsulated into exosomes and are shed into the extracellular environment. All fluids in the human body have been shown to contain exosomes, which can transfer the cytoplasmic ingredients to other cells either locally or at distant sites. The cytoplasmic payload within exosomes, once transferred to the recipient cells, can alter the biology of the recipient cells. Exosomes may be useful for diagnostic purposes since they contain genomic DNA for mutational analysis using a simple blood test. In addition, cancer-derived exosomes have specific markers that enable them to be isolated, purified and analyzed. Exosomes have been described as the package delivery system of the body because of their ability to be released from one cell and deliver their contents to distant cells. This property of exosomes may play an essential role in the formation of certain microenvironments in health and disease.

About Codiak

Codiak BioSciences is a venture-backed start-up dedicated to harnessing the power of exosomes as both therapeutics and diagnostics in cancer and other diseases. Codiak is building a world-class team and has generated, acquired and licensed foundational intellectual property to enable the development of products that capitalize on the unique biology of exosomes.

Contact:
Daniel McIntyre
617-716-9107
dan@publickhousegroup.com

Logo - http://photos.prnewswire.com/prnh/20160104/318954LOGO


'/>"/>
SOURCE Codiak BioSciences Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
2. Kuros Biosurgery Holding Ltd. Closes Merger With Cytos Biotechnology Ltd. Which is Renamed Kuros Biosciences Ltd.
3. Profectus BioSciences Initiates Ebola Vaccine Phase 1 Clinical Trial
4. Lucerne Biosciences Completes Sourcing Investigation into Shires IPR that Led to the Invalidation of the 813 Patent
5. ARMO BioSciences to Present at the 34th Annual J.P. Morgan HealthCare Conference
6. Kindred Biosciences to Provide Corporate Update
7. Sangamo BioSciences Announces Presentation At The 34th Annual J.P. Morgan Healthcare Conference
8. Imago BioSciences Announces Preclinical Data on LSD1 Inhibitor at Annual Meeting of the American Society of Hematology (ASH)
9. Cytos Biotechnology and Kuros Biosurgery to Combine to Create Kuros Biosciences
10. Neurocrine Biosciences to Present at the 27th Annual Piper Jaffray Healthcare Conference
11. Representative Scott Peters Visits Avelas Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/18/2020)... ... 2020 , ... Medial EarlySign , a leader in ... high-burden diseases, and Centric Consulting, a business and technology consulting firm, today announced ... in order to identify and prioritize patients for care. , Combining Centric’s management ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Massachusetts Institute of Technology (MIT) has expanded the company’s exclusive license to ... move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. ...
(Date:7/7/2020)... ... ... R3 International is now offering stem cell therapy for Alzheimers dementia in ... the patient's condition, treatment may be offered IV, intrathecal or with a combination. , ... dementia, and the incidence continues to increase as individuals live longer. There is no ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... competitively procured purchasing contracts to its membership, recently named BioFit Engineered Products ... with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts ...
Breaking Biology Technology:
(Date:9/3/2020)... ... September 03, 2020 , ... Litmus Health , ... third-party assessment of the company’s security practices has been completed. The assessment deemed ... The comprehensive evaluation reviewed Litmus’ processes and systems, assessing them to see whether ...
(Date:8/26/2020)... ... August 25, 2020 , ... Modality Solutions, a biopharmaceutical cold ... Inc. 5000 list. The list is the most prestigious ranking of the nation’s fastest-growing ... for this year’s list, reported three-year revenue growth of 71 percent. , The ...
(Date:8/21/2020)... BOSTON (PRWEB) , ... August 19, 2020 , ... ... , the premier conference and expo uniting life science, data science, informatics and ... keynote sessions. , “In this period of uncertainty and change, Bio-IT takes the ...
Breaking Biology News(10 mins):